Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women.
Premenopausal women meeting operational criteria for idiopathic, acquired, global hypoactive sexual desire disorder were studied in a randomized, double-blind, placebo-controlled, multiple-site escalating dose 112-day trial of bupropion sustained release. Outcome was measured by investigator-rating and self-administered questionnaires. All measures indicated greater sexual responsiveness in women receiving bupropion. The Changes in Sexual Functioning Questionnaire indicated that bupropion had significant effects on increasing measures of sexual arousal, orgasm completion, and sexual satisfaction.
Segraves
Robert Taylor
RT
Department of Psychiatry, Case Western Reserve University and Metro-Health Medical System, 2500 MetroHealth Drive, Cleveland, OH 44109-1998, USA. Rsegraves@metrohealth.org
Clayton
Anita
A
Croft
Harry
H
Wolf
Abraham
A
Warnock
Jill
J
D000328:Adult; D016642:Bupropion / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017697:Premenopause / Q000187:drug effects* / Q000502:physiology / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
D003692:Delayed-Action Preparations; D016642:Bupropion